Details of the Drug Combination

General Information of Drug Combination (ID: DC4LXZ3)

• Drug Combination Name: GDC-0077 + Pyronaridine
• Indication: DD2; Status: Investigative [1]
• Component Drugs:
  GDC-0077 (DMY6WUV): N.A.
  Pyronaridine (DMUWAM2): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DD2
  Zero Interaction Potency (ZIP) Score: 0.349
  Bliss Independence Score: 0.058
  Loewe Additivity Score: 0.01
  LHighest Single Agent (HSA) Score: 0.166

Molecular Interaction Atlas of This Drug Combination

Indication(s) of GDC-0077

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Breast cancer	2C60-2C65	Phase 1	[3]

GDC-0077 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[3]

Indication(s) of Pyronaridine

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[4]

Pyronaridine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	TTZVSJ2	NOUNIPROTAC	Inhibitor	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT04632992) A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.